Table 2.
Comorbidities in the 1,191 subjects by BMI category
| Variable n (%) | Underweight (n = 102) | Normal (n = 480) | Overweight (n = 301) | Obese (n = 229) | Morbidly obese (n = 79) | p value |
|---|---|---|---|---|---|---|
| Diabetes | 14 (13.7) | 97 (20.2) | 79 (26.3) | 81 (35.4) | 23 (29.1) | <0.001 |
| HTN | 30 (39.4) | 171 (35.6) | 123 (40.9) | 107 (46.7) | 34 (43.0) | 0.004 |
| CAD | 8 (7.8) | 51 (10.6) | 36 (12.0) | 26 (11.4) | 6 (7.6) | 0.67 |
| CHF | 7 (6.9) | 48 (10.0) | 29 (9.6) | 27 (11.8) | 18 (22.8) | 0.004 |
| COPD | 4 (3.9) | 34 (7.1) | 16 (5.3) | 17 (7.4) | 7 (8.9) | 0.54 |
| Liver failure | 4 (3.9) | 32 (6.7) | 28 (9.3) | 19 (8.3) | 1 (1.3) | 0.08 |
| HIV | 5 (4.9) | 26 (5.4) | 12 (4.0) | 10 (4.4) | 2 (2.5) | 0.80 |
| Oncology | 49 (48.0) | 164 (34.2) | 97 (32.2) | 72 (31.4) | 9 (11.4) | <0.001 |
| Solid tumor with metastases | 15 (14.7) | 76 (15.8) | 38 (12.6) | 28 (12.2) | 3 (3.8) | 0.07 |
| Lymphoma | 3 (2.9) | 25 (5.2) | 9 (3.0) | 9 (3.9) | 0 (0) | 0.19 |
| Leukemia | 5 (4.9) | 30 (6.3) | 30 (10) | 20 (8.7) | 0 (0) | 0.02 |
| Chemotherapy in the past 4 weeks | 22 (21.6) | 105 (21.9) | 60 (20.0) | 44 (19.2) | 2 (2.5) | 0.003 |
| Immunosuppressed | 32 (31.4) | 172 (35.8) | 102 (33.9) | 67 (29.3) | 7 (8.9) | <0.001 |
| Neutropenia | 4 (3.9) | 24 (5.0) | 9 (3.0) | 11 (4.8) | 0 (0) | 0.24 |
| End-stage renal disease | 7 (6.9) | 39 (8.1) | 21 (7.0) | 19 (8.3) | 6 (7.6) | 0.97 |
| Chronic renal Insufficiency | 14 (13.7) | 73 (15.2) | 53 (17.6) | 39 (17.0) | 10 (12.7) | 0.76 |
| Transplant | 11 (10.8) | 57 (11.9) | 43 (14.3) | 22 (9.6) | 2 (2.5) | 0.06 |
BMI body mass index, HTN hypertension, CAD coronary artery disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus